Maintenance Treatment
49 articles
Time and Hope
Rose farmer Michael Francis wanted more time with his family, so he joined a clinical trial to treat his stage III pancreatic cancer.
Pancreatic Cancer Science—2021 in Review
As the year winds down Let’s Win provides an overall look at the highlights of 2021 in pancreatic cancer science.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Sometimes Things Get Worse Before They Get Better
Matthew Rosenblum thought his time was limited after a pancreatic cancer diagnosis at age 32, but he’s a BRCA2 carrier, which opened treatment options.
Pancreatic Cancer Research Builds Upon Strengths
The September 2023 AACR Special Conference on Pancreatic Cancer focused on the latest research in KRAS, chemotherapy, and cachexia, among other topics.
Far More Time than I Originally Expected
After a Whipple procedure, SBRT, and chemotherapy, Robert Glazier is staying informed about treatment options for pancreatic cancer.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
Choosing Chemo Because I Want to Live
After doing poorly on her first chemotherapy treatments, Catalina Lulley switched doctors because she is determined to survive pancreatic cancer.
AACR Virtual Special Conference on Pancreatic Cancer: Day One Highlights
Let’s Win and the Lustgarten Foundation present highlights of Day One of the AACR Virtual Special Conference on Pancreatic Cancer.
A Charley Horse Led to Pancreatic Neuroendocrine Tumor Discovery
Mark Head thought he had a Charley horse, but it turned out to be a more serious deep vein thrombosis. A scan for the source found a pancreatic neuroendocrine tumor.
Pancreatitis and Pancreatic Cancer
When Wayne was diagnosed with pancreatitis, the tests showed a very high likelihood of pancreatic cancer.